Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, and Synovial Sarcoma
NCT03016819Phase 3
Key facts
- Status
- Recruiting
- Start
- Aug 2017
- Primary completion
- Dec 2027
- Countries
- 5
- Sponsor
- Advenchen Laboratories
- Drugs
- anlotinib
- Conditions
- alveolar soft part sarcoma (ASPS)leiomyosarcoma (LMS)synovial sarcoma (SS)
01
Overview
Phase 3, randomised, double-blind trial of anlotinib in alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS) and synovial sarcoma (SS), sponsored by Advenchen Laboratories. Primary endpoints: Objective Response Rate at 48 months, Progression-Free Survival at 48 months and 1 more. Started Aug 2017; status: recruiting.
02
Design
- Study design
- RandomizedDouble-blind
03
Endpoints
Primary
Objective Response Rate
Progression-Free Survival
Pharmacokinetics and Electrocardiogram Parameters
Secondary
Duration of Response
Objective Response Rate
Beyond the preview
Go deeper on NCT03016819.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016819.